Paradigm Biopharmaceuticals Ltd. (AU:PAR) has released an update.
Paradigm Biopharmaceuticals Ltd. is set to submit a revised Phase 3 trial protocol to the FDA, aiming to enhance patient convenience and reduce costs. The company has shortlisted four global CROs for the trial, with enrollment expected to start in early 2025 at Australian sites. Demonstrating confidence in their progress, Paradigm’s board and staff have purchased shares, highlighting their commitment to advancing the clinical program.
For further insights into AU:PAR stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
